See every side of every news story

Published 1 day ago • loading... • Updated 1 day ago

CARsgen Therapeutics Announces 2025 Interim Results

CARsgen Therapeutics reported revenue of around RMB51 million for the first half of 2025, primarily from zevor-cel.
The company's gross profit was around RMB29 million for the six months ended June 30, 2025.
Zevorcabtagene autoleucel, known as zevor-cel, is approved by NMPA for treating adult patients with multiple myeloma.
The CDE of NMPA accepted a New Drug Application for satri-cel for advanced gastric adenocarcinoma in June 2025.

Insights by Ground AI

Does this summary seem wrong?

56 Articles

56 Articles

+55 Reposted by 55 other sources

CARsgen Therapeutics Announces 2025 Interim Results

SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results.

1 day ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources56

Leaning Left5Leaning Right2Center15Last Updated10 hours agoBias Distribution

68% Center

Bias Distribution

68% of the sources are Center

68% Center

+10

Untracked bias

+25

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States 1 day ago on Friday, August 15, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics